SecBot SecBot
8-K ·Filed Apr 6, 2026

VREOF

Vireo Growth Inc.
MIXED
Impact 7/10
Horizonweeks Processed7mo ago SEC0001104659-26-039924
Killer combo: M&A completed + management change
Actionable Insight ◆ Mixed

Monitor integration of Eaze operations in California, Florida, and Colorado, and watch for shareholder approval of CEO's performance-based equity awards. The Ace Ventures partnership may create near-term cash flow challenges due to the $16 million note structure.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.78
T+0 close · Apr 6, 2026 · via day close
Latest settled
−15.52%
T+60 · $9.95
Vs SPY
−28.79%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 7 $11.78entry
  2. T+1 · 7mo ago +1.88%α −0.66% · $12.00
  3. T+5 · 7mo ago +8.89%α +3.54% · $12.83
  4. T+20 · 7mo ago +6.75%α −3.04% · $12.57
  5. T+60 · 5mo ago −15.52%α −28.79% · $9.95

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vireo Growth Inc. completed its acquisition of Eaze Inc., issuing 90.4 million shares valued at $47 million, and simultaneously restructured its New York operations through a partnership with Ace Ventures. The company also amended its merger agreement and CEO's employment contract, including a potential $2.5 billion equity award contingent on performance milestones.

Key Financial Metrics

Deal Value
$47.0M
Deal Type
acquisition

Key Facts

  • Completed acquisition of Eaze Inc. by issuing 90,379,591 subordinate voting shares valued at $47,040,000
  • Entered into partnership with Ace Venture of NY LLC for Vireo Health of New York, with Ace holding 51% ownership
  • Amended CEO John Mazarakis's employment agreement with potential performance-based equity awards totaling up to 6% of fully diluted equity
  • Issued $16 million promissory note from Vireo Health of New York to Vireo Health Inc. with 7% interest
  • Appointed Michael Steiner to board of directors

Financial Impact

Diluted shareholders by issuing 90.4 million shares for Eaze acquisition and created $16 million intercompany note for New York operations

dilutiondebtequity

Risk Factors

  • Integration risks from combining Eaze's operations
  • Potential dilution from CEO's performance-based equity awards
  • Cash flow timing mismatch in New York operations due to the $16 million note structure

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-039924
Document: tm2611166d1_ex10-2.htm0001104659-26-039924
Document: tm2611166d1_ex2-2.htm0001104659-26-039924
Document: tm2611166d1_ex99-2.htm0001104659-26-039924
Document: tm2611166d1_ex99-1.htm0001104659-26-039924
Document: 0001104659-26-039924-index-headers.html0001104659-26-039924
Document: 0001104659-26-039924-index.html0001104659-26-039924
Document: 0001104659-26-039924.txt0001104659-26-039924

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 6, 2026